AGRANULOCYTOSIS FOLLOWING PHENYLBUTAZONE (BUTAZOLIDIN) THERAPY

2 May 1953

journal article
research article
Published by American Medical Association (AMA) in JAMA

Vol. 152 (1) , 33-36
https://doi.org/10.1001/jama.1953.63690010009007g

Abstract

Extensive clinical trial has shown that phenylbutazone (Butazolidin) is effective in relieving pain and stiffness in such musculoskeletal disorders as gouty arthritis, spondylitis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, fibrositis, muscular rheumatism, myositis, bursitis, sciatica, and periarthritis. Chemically, the drug is 3,5-dioxo-1,2-diphenyl-4n-butyl pyrazolidin sodium. Hence, it is related to aminopyrine (Pyramidon), which chemically is 4-dimethylamino-1-2,3-dimethylpyrazolon. It is significant that no case of fatal agranulocytosis has been reported to date by either American or European investigators in spite of the close relationship between phenylbutazone and aminopyrine. Wilhelmi,¹Belart,²Loewenhardt,³Fähndrich,⁴and Fischer⁵reported that the drug did not influence the blood picture to any appreciable extent. Gsell and Müller⁶reported transient granulocytopenia that did not require discontinuance of the drug. The first American report was by Kuzell, Schaffarzick, Brown and Mankle⁷and concerned the treatment of 140 patients with gout and a variety of rheumatic

Keywords

This publication has 0 references indexed in Scilit: